PUBLISHER: TechSci Research | PRODUCT CODE: 1779035
PUBLISHER: TechSci Research | PRODUCT CODE: 1779035
Menopausal Hot Flashes Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Type, By Treatment Type, By Distribution Channel, By Region and Competition, 2020-2030F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
Global Menopausal Hot Flashes Treatment Market was valued at USD 6.45 billion in 2024 and is expected to reach USD 8.79 billion by 2030 with a CAGR of 5.43% during the forecast period. The global menopausal hot flashes treatment market is evolving rapidly, driven by growing awareness of women's health issues and increasing demand for effective symptom management during menopause. As more women seek relief from the discomfort and disruption caused by hot flashes, the market is witnessing the introduction of a diverse range of treatment options. These include hormone replacement therapies, non-hormonal pharmaceuticals, herbal remedies, and lifestyle-oriented solutions such as dietary supplements and wellness programs.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 6.45 Billion |
| Market Size 2030 | USD 8.79 Billion |
| CAGR 2025-2030 | 5.43% |
| Fastest Growing Segment | Hospital Pharmacies |
| Largest Market | North America |
Pharmaceutical companies are continuously investing in research and development to formulate therapies that are both effective and carry fewer side effects. For example, a December 2023 article in the Journal of the Menopause Society reported findings from an online study involving 12,268 postmenopausal women across countries like Brazil, Canada, Mexico, and several Nordic nations. It revealed that around 15.6% experienced moderate to severe vasomotor symptoms (VMS). This widespread prevalence is anticipated to fuel market growth in the coming years. Hormone-based treatments remain widely used due to their proven efficacy, but concerns around long-term safety have led to a rising interest in non-hormonal alternatives. These alternatives are particularly appealing to women who are unable or unwilling to undergo hormone therapy, fueling innovation in selective serotonin reuptake inhibitors, plant-based treatments, and wearable cooling technologies. In addition to traditional treatment avenues, there is a notable shift toward personalized care and holistic wellness approaches. Healthcare providers are increasingly adopting integrated treatment plans that consider not only physical symptoms but also the emotional and psychological aspects of menopause. Telemedicine platforms and digital health tools are also playing a growing role in patient engagement, enabling better management and follow-up care.
The market is also being shaped by demographic and social changes, such as the growing population of aging women and the destigmatization of menopause in many regions. This cultural shift is empowering more women to seek professional medical help and demand high-quality treatments. As a result, the market is poised for continued growth, with opportunities emerging for both established players and new entrants offering innovative therapies that cater to the diverse and changing needs of menopausal women across the globe.
Key Market Drivers
Rising Awareness of Menopause-Related Health Issues
Rising awareness of menopause-related health issues has become a pivotal force driving the global menopausal hot flashes treatment market. For many years, menopause was considered a private or even taboo topic, leading to limited discussion and a lack of proactive medical engagement. However, in recent years, societal attitudes have shifted significantly. Health organizations, advocacy groups, and media platforms are increasingly highlighting the challenges women face during menopause, especially the disruptive symptoms such as hot flashes, night sweats, and sleep disturbances. This growing visibility has empowered women to seek medical advice and explore available treatment options more confidently. For example, in May 2023, the U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral treatment for moderate to severe vasomotor symptoms, commonly known as hot flashes, associated with menopause. The introduction of such innovative therapies is likely to enhance access to menopausal treatments and support market growth in the coming years.
Educational initiatives and awareness campaigns are playing a critical role in informing women about the physiological changes associated with menopause and the importance of timely intervention. These efforts are not only helping women recognize symptoms earlier but also encouraging open dialogue with healthcare providers. As a result, there is a notable increase in consultations related to menopause management, leading to greater demand for both pharmaceutical and non-pharmaceutical solutions.
Healthcare professionals are also becoming more proactive in addressing menopausal symptoms during routine check-ups, further normalizing the conversation around menopause. At the same time, the digital era has enabled access to a vast pool of information, forums, and telemedicine services, making it easier for women to educate themselves and connect with specialists from the comfort of their homes.
The increased focus on women's health across global health agendas is also pushing policymakers and healthcare providers to prioritize menopause management. This has led to the development of specialized clinics, wellness programs, and tailored treatment regimens, all aimed at improving quality of life during this transition. In turn, this heightened awareness is translating into a larger, more engaged consumer base actively seeking effective solutions for hot flashes, thereby propelling the growth of the menopausal hot flashes treatment market.
Key Market Challenges
Safety Concerns Around Hormone Therapy
Safety concerns around hormone therapy remain one of the most significant challenges in the global menopausal hot flashes treatment market. While Hormone Replacement Therapy (HRT) has long been considered the most effective option for alleviating hot flashes and other vasomotor symptoms associated with menopause, its potential risks have created a climate of caution among both patients and healthcare providers. Studies linking long-term hormone use-particularly estrogen-progestin combinations-to increased risks of breast cancer, blood clots, stroke, and cardiovascular events have led to heightened scrutiny of HRT prescriptions.
These safety concerns have prompted regulatory authorities to issue strict guidelines on the use of hormone therapy, recommending the lowest effective dose for the shortest possible duration. As a result, many women and clinicians are either reluctant to initiate or continue HRT, particularly in cases where the patient has a personal or family history of hormone-sensitive conditions. This has limited the therapy's appeal, despite its proven efficacy, and has created a significant demand for safer, non-hormonal alternatives. Moreover, the fear surrounding hormone therapy has contributed to misinformation and confusion, causing some women to avoid treatment altogether even when they might benefit from it. This underscores the need for clearer patient education and better risk-benefit communication by healthcare professionals.
These ongoing safety concerns are reshaping the treatment landscape, pushing pharmaceutical companies to innovate and develop non-hormonal therapies with better safety profiles. Addressing these concerns effectively is crucial for expanding patient access and building trust in the evolving options available for managing menopausal hot flashes.
Key Market Trends
Growing Preference for Non-Hormonal Therapies
The growing preference for non-hormonal therapies is emerging as a defining trend in the global menopausal hot flashes treatment market. Historically, hormone replacement therapy (HRT) has been the most widely used and effective option for managing vasomotor symptoms like hot flashes. However, concerns surrounding the long-term safety of HRT-including increased risks of breast cancer, stroke, and cardiovascular conditions-have led many women to seek alternative treatments. This shift in preference has opened the door for the development and adoption of non-hormonal therapies that offer relief without the potential complications associated with hormones.
Non-hormonal treatments encompass a wide range of options, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentin, and clonidine. These medications, often prescribed off-label, have shown effectiveness in reducing hot flashes and night sweats. More recently, advancements in drug development have introduced targeted non-hormonal therapies such as neurokinin-3 (NK3) receptor antagonists, which directly act on brain pathways that regulate temperature, offering a novel mechanism of action for symptom relief. In addition to pharmaceuticals, there is increasing consumer interest in herbal supplements and plant-based remedies, such as black cohosh, soy isoflavones, and red clover. These options appeal to women looking for natural or integrative approaches, further broadening the spectrum of non-hormonal interventions. This trend is particularly important for women who are not eligible for HRT due to medical contraindications or personal choice. As healthcare providers become more aware of and confident in these alternatives, and as patients demand safer and more personalized options, the market for non-hormonal therapies is expected to expand significantly. The growing preference for such treatments underscores a broader movement toward risk-averse, patient-centric care and is reshaping the direction of innovation in the menopausal hot flashes treatment landscape.
Key Market Players
- Abbvie, Inc.
- Allergan PLC.
- Bayer Ag.
- Cipla, Inc.
- Eli Lilly and Company.
- Emcure Pharmaceuticals Ltd.
- GSK PLC.
- Glenmark Pharmaceuticals Ltd.
- Hisamitsu Pharmaceutical Co. Inc.
- Merck & Co. Inc.
Report Scope:
In this report, the Global Menopausal Hot Flashes Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Menopausal Hot Flashes Treatment Market, By Type:
- Oral
- Liquid
- Pill
Menopausal Hot Flashes Treatment Market, By Treatment Type:
- Hormonal Treatment
- Non-Hormonal Treatment
- Alternative Treatment
Menopausal Hot Flashes Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Menopausal Hot Flashes Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Menopausal Hot Flashes Treatment Market.
Available Customizations:
Global Menopausal Hot Flashes Treatment Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Menopausal Hot Flashes Treatment Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Type (Oral Liquid v/s Pill)
- 5.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 5.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 5.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 5.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By CompaBy (2024)
- 5.3. Product Map
6. North America Menopausal Hot Flashes Treatment Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Type (Oral Liquid v/s Pill)
- 6.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 6.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 6.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 6.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Menopausal Hot Flashes Treatment Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Type
- 6.3.1.2.2. By Treatment Type
- 6.3.1.2.3. By Distribution Channel
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Menopausal Hot Flashes Treatment Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Type
- 6.3.2.2.2. By Treatment Type
- 6.3.2.2.3. By Distribution Channel
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Menopausal Hot Flashes Treatment Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Type
- 6.3.3.2.2. By Treatment Type
- 6.3.3.2.3. By Distribution Channel
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Menopausal Hot Flashes Treatment Market Outlook
7. Europe Menopausal Hot Flashes Treatment Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Type (Oral Liquid v/s Pill)
- 7.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 7.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 7.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 7.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Menopausal Hot Flashes Treatment Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Type
- 7.3.1.2.2. By Treatment Type
- 7.3.1.2.3. By Distribution Channel
- 7.3.1.1. Market Size & Forecast
- 7.3.2. GermaBy Menopausal Hot Flashes Treatment Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Type
- 7.3.2.2.2. By Treatment Type
- 7.3.2.2.3. By Distribution Channel
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Menopausal Hot Flashes Treatment Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Type
- 7.3.3.2.2. By Treatment Type
- 7.3.3.2.3. By Distribution Channel
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Menopausal Hot Flashes Treatment Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Type
- 7.3.4.2.2. By Treatment Type
- 7.3.4.2.3. By Distribution Channel
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Menopausal Hot Flashes Treatment Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Type
- 7.3.5.2.2. By Treatment Type
- 7.3.5.2.3. By Distribution Channel
- 7.3.5.1. Market Size & Forecast
- 7.3.1. France Menopausal Hot Flashes Treatment Market Outlook
8. Asia-Pacific Menopausal Hot Flashes Treatment Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Type (Oral Liquid v/s Pill)
- 8.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 8.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 8.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 8.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Menopausal Hot Flashes Treatment Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Type
- 8.3.1.2.2. By Treatment Type
- 8.3.1.2.3. By Distribution Channel
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Menopausal Hot Flashes Treatment Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Type
- 8.3.2.2.2. By Treatment Type
- 8.3.2.2.3. By Distribution Channel
- 8.3.2.1. Market Size & Forecast
- 8.3.3. Japan Menopausal Hot Flashes Treatment Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Type
- 8.3.3.2.2. By Treatment Type
- 8.3.3.2.3. By Distribution Channel
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea Menopausal Hot Flashes Treatment Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Type
- 8.3.4.2.2. By Treatment Type
- 8.3.4.2.3. By Distribution Channel
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Menopausal Hot Flashes Treatment Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Type
- 8.3.5.2.2. By Treatment Type
- 8.3.5.2.3. By Distribution Channel
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Menopausal Hot Flashes Treatment Market Outlook
9. South America Menopausal Hot Flashes Treatment Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Type (Oral Liquid v/s Pill)
- 9.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 9.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 9.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 9.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Menopausal Hot Flashes Treatment Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Type
- 9.3.1.2.2. By Treatment Type
- 9.3.1.2.3. By Distribution Channel
- 9.3.1.1. Market Size & Forecast
- 9.3.2. Argentina Menopausal Hot Flashes Treatment Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Type
- 9.3.2.2.2. By Treatment Type
- 9.3.2.2.3. By Distribution Channel
- 9.3.2.1. Market Size & Forecast
- 9.3.3. Colombia Menopausal Hot Flashes Treatment Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Type
- 9.3.3.2.2. By Treatment Type
- 9.3.3.2.3. By Distribution Channel
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Brazil Menopausal Hot Flashes Treatment Market Outlook
10. Middle East and Africa Menopausal Hot Flashes Treatment Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Type (Oral Liquid v/s Pill)
- 10.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 10.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 10.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 10.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Menopausal Hot Flashes Treatment Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Type
- 10.3.1.2.2. By Treatment Type
- 10.3.1.2.3. By Distribution Channel
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Saudi Arabia Menopausal Hot Flashes Treatment Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Type
- 10.3.2.2.2. By Treatment Type
- 10.3.2.2.3. By Distribution Channel
- 10.3.2.1. Market Size & Forecast
- 10.3.3. UAE Menopausal Hot Flashes Treatment Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Type
- 10.3.3.2.2. By Treatment Type
- 10.3.3.2.3. By Distribution Channel
- 10.3.3.1. Market Size & Forecast
- 10.3.1. South Africa Menopausal Hot Flashes Treatment Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Development
- 12.2. Mergers & Acquisitions
- 12.3. Product Launches
13. Global Menopausal Hot Flashes Treatment Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
15.1 Abbvie, Inc.
15.2 Allergan PLC.
15.3 Bayer Ag.
15.4 Cipla, Inc.
15.5 Eli Lilly and CompaBy.
15.6 Emcure Pharmaceuticals Ltd.
15.7 GSK PLC.
15.8 Glenmark Pharmaceuticals Ltd.
15.9 Hisamitsu Pharmaceutical Co. Inc.
15.10 Merck & Co. Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
